<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325688</url>
  </required_header>
  <id_info>
    <org_study_id>PEP005-037</org_study_id>
    <nct_id>NCT01325688</nct_id>
  </id_info>
  <brief_title>PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities</brief_title>
  <official_title>A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peplin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peplin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is primarily designed to investigate whether treatment, once daily for up to three
      consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in
      patients with superficial Basal Cell Carcinoma (sBCC) lesions on the trunk and extremities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related Adverse Events, Local Skin Responses; Pigmentation and scarring</measure>
    <time_frame>120 days</time_frame>
    <description>Number of participants with treatment related Adverse Events, change from baseline in LSR and pigmentation and scarring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological and clinical clearance of sBCC lesions.</measure>
    <time_frame>120 days</time_frame>
    <description>Number of participants with histological and clinical clearance of sBCC lesions.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Superficial Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEP005 0.05% applied with no occlusion for up to three consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 (ingenol mebutate) Gel, 0.05%</intervention_name>
    <description>PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aluminium disk</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OpSite(TM) disk</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be male or female and at least 18 years of age

          -  Female patients must be of: non-childbearing potential or if of childbearing potential
             then have a negative serum and urine pregnancy test and using effective contraception

          -  Ability to provide informed consent

          -  primary diagnosed and histologically confirmed sBCC located on the trunk or
             extremities which is suitable for excision

        Exclusion Criteria:

          -  location of the sBCC lesion within 10cm of an incompletely healed wound, on the hand
             or foot, on the breast of women, on the anogenital area.

          -  Undergone cosmetic or therapeutic procedures within 2cm of the selected treatment area
             in the 2 weeks prior to the screening visit.

          -  Use of acid-containing therapeutic products within 2 cm of the selected treatment area
             in the 2 weeks prior to the screening visit

          -  Use of topical moisturisers/creams/lotions (non-medicated/non-irritant salves are
             acceptable), artificial tanners or topical steroids: within 2 cm of the selected
             treatment area.

          -  Have received treatment with immunomodulators, or interferon/interferon inducers,
             systematic medications that suppress the immune system or UVB in the last 4 weeks

          -  Have undergone treatment with 5-FU, imiquimod, diclofenac or photodynamic therapy
             within 2 cm of the selected treatment area within 8 weeks prior to any screening
             visit.

          -  Use of systemic retinoids.

          -  Those who are currently participating in any other clinical trial

          -  Those known or suspected of not being able to comply with the requirements of the
             protocol

          -  Females who are pregnant or are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Morley</last_name>
    <role>Study Director</role>
    <affiliation>Peplin Operations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southderm Pty Ltd</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Dermatology</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialist Connect</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Institute of Victoria</name>
      <address>
        <city>South Yarra</city>
        <state>Victoria</state>
        <zip>3141</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John of God Dermatology</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burswood Dermatology</name>
      <address>
        <city>Victoria Park</city>
        <state>Western Australia</state>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.tga.gov.au</url>
    <description>Therapeutic Goods Administration</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <disposition_first_submitted>December 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 5, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 7, 2014</disposition_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PEP005</keyword>
  <keyword>Peplin</keyword>
  <keyword>sBCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

